Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (February 2018)

46 slides from Windtree Therapeutics's investor presentation, Feb 27, 2018

  1. Slide 1: Corporate Presentation February 2018

    Se Ze WINDTREE Corporate Presentation February 2018 OTCQB:WINT

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreem

  3. Slide 3: Windtree Therapeutics

    Windtree Therapeutics = Public, small cap biopharmaceutical / medical device company = Based in Warrington, PA with approximately 27 employees = Focused in the acute respiratory area with a lead program expected to address a significant need and expand the Respiratory Distress Syndrome (RDS) in prem

  4. Slide 4: Respiratory Distress Syndrome (RDS)

    Respiratory Distress Syndrome (RDS) Primary characteristic is surfactant deficiency in underdeveloped lungs of premature infants (born with a lack of natural lung surfactant required for open airways and proper gas exchange — O, in and CO, out) American Academy of Pediatrics guidelines recommend pro

  5. Slide 5: Prevalence of RDS Spans Across Gestational Ages / Severity

    Prevalence of RDS Spans Across Gestational Ages / Severity % of RDS Population RDS Prevalence i <26 weeks GA >95% 26-28 weeks GA 85-95% AEROSURF® Clinical Development Program @ 29-32 weeks GA 65-75% 33-34 weeks GA 40-50% 35-36 weeks GA 5-10% LOWER Size of Sub-Population HIGHER 30% nCPAP 4+ line 55%

  6. Slide 6: Current RDS Treatment Pathways

    Current RDS Treatment Pathways Initial treatment options include invasive and non-invasive methods: Surfactant Invasive mechanical nCPAP Support until presumptive Therapy + ventilation (IMV) endogenous surfactant production * Animal-derived surfactant | + Requires sustained + Non-invasive nasal deli

  7. Slide 7: Clinicians Seeking a Noninvasive Way to Deliver Surfactant

    Clinicians Seeking a Noninvasive Way to Deliver Surfactant What is wanted: Vv Avoid the risks and complications associated with delivery of surfactant therapy via intubation and mechanical ventilation Y Possibility of repeat doses Y Avoid clinical instability associated with administration of liquid

  8. Slide 8: Windtree Technology Platform - AEROSURF

    Windtree Technology Platform - AEROSURF® Potential to Provide Both Non-Invasive and Invasive Solutions to Treat RDS Proprietary Synthetic KL4 Surfactant Designed to be structurally similar to human Designed specifically to aerosolize lung surfactant and deliver KLa surfactant Liquid KL surfactant (i

  9. Slide 9: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® Surfactant Therapy ncPAP Respiratory Support RISKS respiration Surfactant therapy delivers near-immediate clinical improvement Reversing surfactant deficieney.has /a profound positive impact on\ BPD Infection, ventilator-induced pneumonia cord damage, asthma, lu

  10. Slide 10: Potential Drivers of AEROSURF Opportunity

    Potential Drivers of AEROSURF® Opportunity #1 stated unmet need in RDS 20-30% reduction in nCPAP failure is meaningful “Noninvasive Results in >40% surfactant delivery” reported = 54% top, unaided expected response (3x higher , patient share~ than next response) 1, N=278 Neonatalogists, US & EU; WIN

  11. Slide 11: Significant RDS Global Revenue Opportunity

    Significant RDS Global Revenue Opportunity U.S. Market Example: ~385,000 preterm infants per year, ~134,000 with RDS China Market: ~1.2-1.4MM preterm, ~500,000 -635,000 with RDS Estimated 2016 * Globally, only 50% to 60% of (SUL RSS RDS patients currently treated with surfactant therapy * Opportunit

  12. Slide 12: China Opportunity — License with Lee's Pharm

    China Opportunity — License with Lee’s Pharm = Currently, the top animal-derived surfactant sales market, but still very underpenetrated 16-19MM births / year (compared to 4MM in the U.S.) * About 1.2- 1.4MM are premature and 500,000-600,000 have RDS = New second child policy promoted by China gover

  13. Slide 13: Medical Device and Device Studies

    Medical Device and Device Studies

  14. Slide 14: Innovative Aerosol Delivery System (ADS)

    Innovative Aerosol Delivery System (ADS) Proprietary Innovative Aerosol Delivery System (ADS) Be peer Designed specifically to aerosolize and deliver KLa surfactant * AEROSURF® innovation made possible by novel medical device * Unique aerosol delivery system (ADS) technology utilizing pressure and h

  15. Slide 15: ADS Technology Provides Better Output Rate

    ADS Technology Provides Better Output Rate Aerosolizes surfactant as well as saline Aerosol output rate Output with Saline (mL/minute) Output with KL, Surfactant (30mg TPL/mL) Owe _— g 0! g 08 Eo. Eo 19 0.0 0.0 g & eo - * Saline output of ADS technology is close to KL, surfactant output of ADS techn

  16. Slide 16: Lung Deposition Study in Non-Human Primates

    Lung Deposition Study in Non-Human Primates * Use of non-human primates (cynomolgus macaques) - Nose, throat, & lung anatomy comparable to infants; respiratory function similar to preterm infants * Radiolabeled KL4 surfactant aerosolized using Aerosol Delivery System (ADS), delivered via nasal cannu

  17. Slide 17: AEROSURF Clinical Studies

    AEROSURF” Clinical Studies

  18. Slide 18: AEROSURF Phase Program Components

    AEROSURF” Phase 2 Program Components Study / Acti Phase 2a 2a Expansion Phase 2a Phase 2b Other Studies: Observational Study Lung Deposition Study Other Activitie: Licensing in Asia Device Development FDA Interaction Rationale / Objective Initial safety & tolerability (29-34 wk gestational age (GA))

  19. Slide 19: nCPAP Failure through hours by dose group

    45 and 60 Minute Dose Groups - nCPAP Failure through 72 hours Time to nCPAP Failure Time Until any Intubation - Dosing Group 3&4 Data 01708/2016 100% 21/40 20% + ‘Subjects Not Intubated (%) g Percent Subjects Failed a — . 0% ° 2 » % “ o n CPAP Only 75 & 100 me/ke (45.8 60 min) Hours from Randomizati

  20. Slide 20: AEROSURF Safety and Tolerability Assessment

    AEROSURF® Safety and Tolerability Assessment = The FDA requested that we conduct a separate safety study in smaller premature infants before including them in blinded studies = Multicenter, randomized, open-label, controlled study in 48 premature infants 26 to 28 weeks GA receiving nCPAP for RDS to

  21. Slide 21: AEROSURF Observation Related to Bronchopulmonary Dysplasia (BPD)

    Sew @ AEROSURF® Potentially Important Observation Related to Bronchopulmonary Dysplasia (BPD) A @: BPD Rate Patients AEROSURF 0% 0/24 Control 25% 6/24 . Bronchopulmonary Dysplasia (BPD) or chronic lung disease of the newborn is one of the most common complications of prematurity and RDS treatments.

  22. Slide 22: AEROSURF Phase 2b Trial Design

    AEROSURF* (28 to 32 wk GA) Trial Objectives Trial Design 221 Patients Enrolled * Evaluate safety and tolerability * Demonstrate efficacy * Determine effect size for phase 3 planning * Dose(s) selection for phase 3 * Evaluate and further develop our Phase 2 prototype device performance Sie wINDTREE B

  23. Slide 23: AEROSURF Phase 2b Incidence of nCPAP Failure

    AEROSURF® Phase 2b Incidence of nCPAP Failure Preplanned mITT Without Treatment Interruptions Demonstrates Targeted Reduction * US Only All Sites (to compare with 2a) 45% Aas Aas 60% 27% sox 50% 40% + relative ~ k aor reduction 38% elative 50% 7 Reduction — 35% 32% 30% 30% _ 17% 25% 10% % 0% 20' \CP

  24. Slide 24: AEROSURF Significantly Improved Key Respiratory Parameters

    AEROSURF® Significantly Improved Key Respiratory Parameters 08 O, Saturation / FiO, Ratio Change from Dose Init All Dosed Patient Population 80 mele os enc AP Only 40 mg/kg showed a similar pattern 04 with an intermediate effect 03 * 02 01 @ — Baseines/ Baseines/F Baseines/F 80 mg TPL kg 3.0,n=67 20

  25. Slide 25: Potential for Reduced Respiratory Support in Patients Who Failed nCPAP

    AEROSURF® - Potential for Reduced Respiratory Support in Patients Who Failed nCPAP When on AEROSURF re 120 3 10 0 0 “0 2 ° 80 mg/kg CPAP Only 80 mg/kg CPAP Only (n=27) (n=23) (n=30) (n=29) Mechanical Ventilation Supplemental Oxygen In patients who failed nCPAP and required intubation and mechanical

  26. Slide 26: Safety & Tolerability Profile

    - Safety & Tolerability Profile Similar for Treatment and Control Populations = The adverse event and serious adverse event profile was similar across the 3 groups = Complications of prematurity were also similar 40 (4 80 kg nCPAP Only (25 min) (50 min) Acquired Sepsis 12 (17%) 13 (18%) 16 (23%) Air

  27. Slide 27: Summary of Efficacy Signals in the Phase 2 Program

    Summary of Efficacy Signals in the Phase 2 Program Post-hocpooled analysis of Phase? failurerates ‘oie = Post-hoc pooled analysis of patients inthe — 50% 20%, relative phase 2 program (3 studies) treated in 40% 36% ee ai doses > 45 minutes dosed as intended 30% (uninterrupted) shows a notablereducti

  28. Slide 28: Evolution of Aerosolized Delivery System from Phase 2 to Next Generation

    Evolution of Aerosolized Delivery System (ADS) from Phase 2 to the Next Generation, Phase 3 / “Go to Market” Device Phase 2 Phase 3 / Commercial * 2012-2017 * 2018 and beyond * Developed in conjunction with Battelle * Developing in collaboration with Memorial Institute (Battelle) Battelle * Designed

  29. Slide 29: Complete Device Development and Transition to Enhanced Next Generation ADS in 2Q 2018

    Complete Device Development and Transition to Enhanced Next Generation ADS in 2Q 2018 Next Generation ADS will be Phase 3 and “Go to Market” Device = Designed to utilize the same aerosol delivery technology to provide comparable key aerosol characteristics of emitted dose and particle size of the ph

  30. Slide 30: Addressing Filter Issue Through Design Enhancements, Quality Systems and Assembly

    Addressing Filter Issue Through Design Enhancements, Quality Systems and Assembly. Demonstrating in a Performance Study ¥ Filter diameter doubled, surface cross section é increased by 4x v New material quality specifications and tests for flow through filter ‘ow tougher Fier ing measure v Modified d

  31. Slide 31: AEROSURF Clinical Development Next Steps for 2018

    AEROSURF® Clinical Development Next Steps for 2018 Generate the strongest possible position and transition to phase 3 Execute a Bridge Study to transition the new, Next Gen ADS device in order to meet the following objectives: 1. Demonstrate adequate, consistent performance for the new Next Gen devi

  32. Slide 32: AEROSURF Bridge Study

    AEROSURF® Bridge Study = Blinded study; nCPAP alone as control versus adding AEROSURF® treatment = GA range: 26-32 weeks = N=70 planned (35 per group) in a design similar to phase 2b = ~20-25 select sites * represent the best previous study sites for enrollment and execution in phase 2 (predominatel

  33. Slide 33: Program Evolution and Changes to Increase Probability of Technical Success

    Program Evolution and Changes Intended to Increase the Probability of Technical Success and Continue to Strengthened Data = We have reproduced positive results in our Phase 2a and Phase 2b and have learning’s to apply in trial design and execution = Utilize the Next Gen ADS which is designed to miti

  34. Slide 34: Other Potential Development Activities

    Other Potential Development Activities - Lyophilized Lucinactant (LS) - Preclinical Activities B ex 2 WINDTREE

  35. Slide 35: Lyophilized Lucinactant

    Lyophilized Lucinactant A Second Asset Can Expand the Opportunity = Lyophilized dosage form of our KLa surfactant drug product that was previously approved by the FDA as a liquid dosage form = Currently used in AEROSURF® development program = Improvements and benefits (besides being fully synthetic

  36. Slide 36: Leverage Technology to Advance Acute Pulmonary Disease Care Beyond RDS

    Leverage our Innovative Technology to Advance Acute Pulmonary Disease Care and Outcomes Beyond RDS Program Focus Potential Application Richie Metastatic Breast & Lung ALI - Radiation —_ | eu=adlean | chronic changes (fibrotic) ad-One; Biodefense “Vi at Mitigate lung injury, SARS, H1N1, MERS, UNA Eic

  37. Slide 37: Platform Exclusivities

    Platform Exclusivities Broad Multi-Faceted Exclusivity Portfolio Regulatory ¢ Orphan Drug Designation in RDS for the U.S. and EU Ep) A ¢ AEROSURF® FDA Fast-Track Designation r sini PUROPEAN MEDICINES AEN = Lyophilized KL4 Surfactant Portfolio - to 2033 = Aerosol Delivery System Portfolio - through 2

  38. Slide 38: Q4 2017 Financial Restructuring Initiative

    Q4 2017 Financial Restructuring Initiative = Our KL4 platform assets represent a significant opportunity, however significant additional investment is required to advance and realize the full potential of these assets = Securing the required additional capital had been a challenge due in significant

  39. Slide 39: Elements of the Q4 2017 Transactions Lee's Share Purchase

    Elements of the Q4 2017 Transactions 1 Lee’s Share Purchase * Lee’s purchased $10 million of common stock * Lee’s owns approximately 73% of currently outstanding Windtree shares of common stock Deerfield Debt Retirement 2 + Deerfield agreed to restructure and retire its $25 million secured loan to f

  40. Slide 40: Results and Benefits of the Restructuring Initiative

    Results and Benefits of the Restructuring Initiative V4 Significantly improved capital structure by removing-the financial overhang of long-term debt CV Lowered the ongoing, non-program related cash burn rate through a combination of a 40% headcount reduction and other cost cutting measures vA Bette

  41. Slide 41: Stated Rationale and Intent of Lee's

    Stated Rationale and Intent of Lee’s 1. High belief in the assets and program © Dr Li, CEO of Lee’s Pharm, has followed Windtree for some time and is compelled by the synthetic surfactant platform (both aerosolized and non- aerosolized in RDS as well as other potential indications) and the significa

  42. Slide 42: 2017 - A Productive Year for Windtree

    2017 - A Productive Year for Windtree 2b Study in 28-32 wkGA 2a Study in 26-28 wkGA 2017 Accomplishments GS winDTREE @ a2

  43. Slide 43: 2018 Objectives

    2018 Objectives Complete Device Development delivering an extremely consistent, high performing Phase 3 / “go to market” drug delivery platform Solid execution in the clinic with the Bridge Study AEROSURF and Lyo Lucinactant LS Global Regulatory Clarity and employed in development Successful funding

  44. Slide 44: AEROSURF Development and Deliverables Overview

    AEROSURF® Development and Deliverables Overview 2018 12019 Clinical Start Up Acti EU —Scientific Advice EU Ped. Investigation Plan (PIP) Regulatory A FDA = Advice Medical Devie =f Plan (PSP) Review 1H2018 2H 2018 through Mid-2019 v Next Gen Device DV v Bridge Study top-line data Y Device Performance

  45. Slide 45: Value Creating Potential

    Value Creating Potential Se i) WINDTREE THERAPEUTICS = Potentially transformative therapy addressing both the unmet efficacy and safety needs in the important, acute neonatology market = Multiple phase 2 clinical trials reproducing efficacy while continuing to build safety and tolerability data base

  46. Slide 46: Striving to deliver Hope for a Lifetime!

    “Striving to deliver Hope for a Lifetime!” Sie wINDTREE @e@

Windtree Therapeutics — Investor Presentation (February 2018) on 6ix